435 results on '"Sikirica, Vanja"'
Search Results
2. Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia
3. Abstract 4143004: A Stepwise Approach to Identifying and Assessing the Content Validity of Patient-Reported Outcome (PRO) Measures for Use with Adults with Acute Heart Failure
4. Development of a signs and symptoms outcome measure for caregivers of patients with methylmalonic acidemia and propionic acidemia (MMAPAQ)
5. Publisher Correction: Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia
6. Author Correction: Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia
7. Retrospective study of propionic acidemia using natural language processing in Mayo Clinic electronic health record data
8. Costs and Treatment Patterns Among Patients with Atopic Dermatitis Using Advanced Therapies in the United States: Analysis of a Retrospective Claims Database
9. Survival of propionic acidemia patients with liver transplant
10. Economic Burden and Healthcare Resource Use of Alopecia Areata in an Insured Population in the USA
11. Development of a conceptual model and patient-reported outcome measures for assessing symptoms and functioning in patients with heart failure
12. Patient Perspectives of the Social, Emotional and Functional Impact of Alopecia Areata: A Systematic Literature Review
13. Unmet Needs Associated with Attention-Deficit/Hyperactivity Disorder in Eight European Countries as Reported by Caregivers and Adolescents: Results from Qualitative Research
14. The Burden of Congestion in Patients Hospitalized With Acute Decompensated Heart Failure
15. Patient-Reported Symptoms and Disease Impacts in Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 2b Study With Abrocitinib
16. Establishing a Core Outcome Measure for Fatigue in Patients on Hemodialysis: A Standardized Outcomes in Nephrology–Hemodialysis (SONG-HD) Consensus Workshop Report
17. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany
18. Symptoms and impacts in anemia of chronic kidney disease
19. Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial
20. The Caregiver Perspective on Paediatric ADHD (CAPPA) survey: Understanding sociodemographic and clinical characteristics, treatment use and impact of ADHD in Europe
21. Patient characteristics associated with all-cause healthcare costs of alopecia areata in the United States
22. MaP NATURAL HISTORY STUDY: CLINICAL AND BIOMARKER FINDINGS IN PROPIONIC ACIDEMIA
23. MaP NATURAL HISTORY STUDY: CLINICAL AND BIOMARKER FINDINGS IN METHYLMALONIC ACIDEMIA DUE TO MUT DEFICIENCY
24. RETROSPECTIVE STUDY OF PROPIONIC ACIDEMIA USING NATURAL LANGUAGE PROCESSING IN MAYO CLINIC EHR DATA
25. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder
26. Optimizing the Use of Electronic Data Sources in Clinical Trials: The Technology Landscape
27. Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison
28. Treatment Patterns among Children and Adolescents with Attention-Deficit/Hyperactivity Disorder with or without Psychiatric or Neurologic Comorbidities in Sweden: A Retrospective Cohort Study
29. Correction to: Development of a conceptual model and patient-reported outcome measures for assessing symptoms and functioning in patients with heart failure
30. A survey study of self‐reported comorbidities among adults with vitiligo in the United States
31. Retrospective Study of Propionic Acidemia Using Natural Language Processing in Mayo Clinic Electronic Health Record Data
32. Prevalence of Vitiligo among Children and Adolescents in the United States
33. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: A randomized, controlled, Phase III trial
34. Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study
35. Impact of Mental Health Comorbidities on Health Care Utilization and Expenditure in a Large US Managed Care Adult Population with ADHD
36. Systematic literature review of the epidemiology of glycogen storage disease type 1a.
37. Economic Impact of Childhood and Adult Attention-Deficit/Hyperactivity Disorder in the United States
38. Comorbidities, Healthcare Utilization, and Costs Associated With Alopecia Totalis and Alopecia Universalis in the United States
39. Impact of nonsegmental vitiligo on patients’ health-related quality of life in the United States
40. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate
41. Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial
42. Unmet Needs Associated with Attention-Deficit/Hyperactivity Disorder in Eight European Countries as Reported by Caregivers and Adolescents: Results from Qualitative Research
43. Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research
44. Assessment of the Psychometric Properties of the Short‐Form Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ‐12) following Surgical Placement of Prolift+M: A Transvaginal Partially Absorbable Mesh System for the Treatment of Pelvic Organ Prolapse
45. Healthcare Utilization and Costs Among US Adolescents With Alopecia Areata
46. Chronic Myeloid Leukemia: Part I—Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States
47. All-cause health care resource utilization and costs among adults with alopecia areata: A retrospective claims database study in the United States
48. Economic impact of childhood/adolescent ADHD in a European setting: the Netherlands as a reference case
49. Extended-release guanfacine hydrochloride in 6–17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study
50. The burden of uterine fibroids in five European countries
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.